Ticker: LYEL

Company Overview: Lyell Immunopharma, Inc. (NASDAQ: LYEL) specializes in developing CAR T-cell therapies for hematologic malignancies and solid tumors. Their lead product, LYL314, aims to enhance response rates in large B-cell lymphoma patients. The company is currently transitioning its manufact...